Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and PK of ONO-2910 in Japanese and Caucasian Subjects
Latest Information Update: 19 May 2021
At a glance
- Drugs ONO-2910 (Primary)
- Indications Peripheral nerve injuries; Peripheral nervous system diseases
- Focus Adverse reactions; First in man
- Sponsors Ono Pharmaceutical
Most Recent Events
- 13 May 2021 Status changed from active, no longer recruiting to completed.
- 06 Dec 2020 Status changed from recruiting to active, no longer recruiting.
- 12 Aug 2020 New trial record